There's a case presentation on pheochromocytoma So tell me everything about anaesthesia considerations for pheochromocytoma,what is the Pathophysiology and anaesthesia management Tell me the most common viva question with answers And also in the end make a good 10 marks answer for theory paper also

Reading File

Finding Sources

Searching PubMed

pheochromocytoma anesthesia management perioperative

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have all the information needed to write a comprehensive, exam-ready answer. Let me compile everything.

Pheochromocytoma: Anaesthesia Considerations - Complete Guide

PART 1: PATHOPHYSIOLOGY

What is a Pheochromocytoma?

A pheochromocytoma is a catecholamine-secreting tumor arising from chromaffin cells of the adrenal medulla (or extra-adrenal paraganglia). The "Rule of 10s" classically describes it:

10% bilateral
10% extra-adrenal (paraganglioma)
10% malignant
10% familial
10% in children

(Modern data suggests higher rates: ~15-25% malignant, ~40% hereditary)

Catecholamine Excess - The Core Problem

The tumor autonomously secretes epinephrine, norepinephrine, and dopamine in excess, bypassing normal feedback mechanisms. Adrenal pheochromocytomas primarily secrete epinephrine, while extra-adrenal tumors (lacking phenylethanolamine N-methyltransferase) secrete predominantly norepinephrine.

Downstream effects:

Catecholamine	Receptor	Effect
Norepinephrine	α1	Vasoconstriction, severe hypertension
Epinephrine	β1	Tachycardia, arrhythmias, increased contractility
Epinephrine	β2	Bronchodilation, peripheral vasodilation
Epinephrine/NE	α2	Inhibits insulin release → hyperglycemia

Pathophysiologic consequences:

Hypertension - paroxysmal (50%), sustained (25%), sustained with paroxysms (25%)
Catecholamine cardiomyopathy - dilated or hypertrophic; from chronic catecholamine toxicity
Volume depletion - chronic vasoconstriction causes reduced plasma volume; patients are relatively hypovolemic despite hypertension
Hyperglycemia - α2-mediated suppression of insulin release + catecholamine-induced gluconeogenesis
Polycythemia - NE stimulates erythropoietin
End-organ damage - renal, cardiac, cerebrovascular

Classic Triad (Headache + Palpitations + Diaphoresis)

This triad with hypertension has >90% sensitivity and specificity for pheochromocytoma.

PART 2: ANAESTHESIA MANAGEMENT

A. PREOPERATIVE PREPARATION (Most Critical Phase)

The goal is to normalize blood pressure, heart rate, and restore plasma volume before surgery. Mortality has fallen from ~50% (pre-blockade era) to <2-3% with proper preparation.

Duration: Begin 1-3 weeks before surgery (longer in severe cases with cardiac/renal comorbidities).

Step 1: Alpha-Adrenergic Blockade FIRST (mandatory before beta-blockade)

Drug	Mechanism	Details
Phenoxybenzamine	Non-selective, irreversible α1+α2 blocker	Gold standard; 10-40 mg/day, titrate up; long half-life; causes reflex tachycardia
Doxazosin	Selective, competitive α1 blocker	Increasingly preferred; less postoperative hypotension; better tolerated
Prazosin	Selective α1 blocker	Short-acting alternative

Why alpha before beta? Giving beta-blockers first in a high-catecholamine state leaves α-receptors unopposed → can precipitate hypertensive crisis. Alpha blockade must precede beta blockade - this is a cardinal rule.

Adequacy criteria for preoperative alpha blockade:

BP < 130/80 mmHg for 24 hours preoperatively
No BP >160/90 in 1 week prior
Orthostatic hypotension present (SBP drop >10-20 mmHg on standing - confirms adequate blockade)
Nasal stuffiness (α-blockade effect)
No ST-T changes
ECG: <1 PVC every 5 minutes

Step 2: Beta-Blockade (only AFTER adequate alpha blockade)

Added if reflex tachycardia (HR >100) persists after alpha-blockade
Use propranolol, atenolol, or metoprolol
Esmolol is ideal intraoperatively (short-acting)
Never start beta-blockers before alpha-blockers

Step 3: Volume Expansion

Patients are chronically volume-depleted
Encourage high-salt diet + increased oral fluids in the days before surgery
IV fluids (1 litre NS or colloid) the night before surgery
Critical to prevent severe hypotension after tumor removal

Other Preoperative Drugs

Calcium channel blockers (nicardipine, amlodipine) - effective as primary or adjunct agents; especially useful if BP <120 mmHg (no blockade needed)
Metyrosine (alpha-methyltyrosine) - inhibits tyrosine hydroxylase, reduces catecholamine synthesis by 40-80%; used in refractory cases or high-risk tumors
Genetic counseling - all patients should undergo germline testing (MEN2, VHL, NF1, SDH mutations affect surgical approach)

B. INTRAOPERATIVE MANAGEMENT

Monitoring

Arterial line (mandatory, placed before induction - beat-to-beat BP monitoring)
Central venous line (CVP monitoring and vasoactive drug administration)
ECG (continuous - detect arrhythmias)
Swan-Ganz catheter - in patients with CHF, CAD, or severe cardiomyopathy
Pulse oximetry, ETCO2, urine output
Blood glucose monitoring

Induction

Goals: Avoid sympathetic stimulation. Smooth, deep induction.

Preferred agents:

Propofol - drug of choice for induction; reduces sympathetic tone
Thiopentone - acceptable alternative
Vecuronium or rocuronium - preferred muscle relaxants (do NOT use succinylcholine - causes fasciculations that can stimulate catecholamine release; do NOT use pancuronium - vagolytic, causes tachycardia; do NOT use atracurium - histamine release)
Fentanyl (high dose) or remifentanil - for blunting laryngoscopy response
Avoid: Ketamine (sympathomimetic, stimulates catecholamine release), morphine (histamine release), halothane (sensitizes myocardium to arrhythmias)

Maintenance

Isoflurane or sevoflurane - preferred volatile agents (minimize cardiac sensitization)
Enflurane - also acceptable
Avoid halothane - sensitizes myocardium to catecholamine-induced arrhythmias
Total IV anaesthesia (TIVA) with propofol + remifentanil is an excellent option

Intraoperative Hypertensive Crisis Management

Events triggering crises: intubation, abdominal insufflation (laparoscopy), tumor manipulation.

Drug	Route	Use
Sodium nitroprusside	IV infusion	First choice; rapidly titratable vasodilator
Phentolamine	IV bolus 1-5 mg	Alpha-blocker for acute hypertensive spikes
Nicardipine	IV infusion	Calcium channel blocker; reliable
Nitroglycerin	IV infusion	Useful for coronary vasospasm-related events
Magnesium sulfate	IV	Inhibits catecholamine release + vasodilator
Esmolol	IV bolus/infusion	For tachycardia/arrhythmias
Lidocaine	IV	For arrhythmias

Hypotension After Tumor Ligation

The critical moment is ligation of the adrenal vein - catecholamine levels drop sharply.

Volume load aggressively with crystalloids/colloids
Norepinephrine infusion - vasopressor of choice
Phenylephrine - pure alpha agonist, useful
Stop or reduce vasodilator infusions
Anticipate and prepare before vessel ligation

Surgical Approach

Laparoscopic adrenalectomy: standard for tumors <5 cm
Open approach: for tumors >5-6 cm, suspected malignancy, or bilateral disease
Fentanyl, ketamine, and morphine should be avoided (can trigger catecholamine release from tumor)

C. POSTOPERATIVE MANAGEMENT

Common postoperative complications:

Complication	Mechanism	Management
Hypotension	Loss of adrenergic stimulation + vasodilation + alpha-blocker effect (PBZ has very long half-life)	IV fluids + vasopressors (NE); usually 20-70% of patients require vasopressors
Hypoglycemia	Rebound insulin surge (removed α2-mediated insulin suppression)	Dextrose infusion + hourly glucose monitoring
Residual hypertension	Residual tumor, second tumor, or secondary HTN	Continue antihypertensives
Adrenal insufficiency	Bilateral adrenalectomy	Corticosteroid replacement

ICU admission - mandatory for 24-48 hours minimum
Monitor BP, blood glucose every 1-2 hours
Restart oral intake early to prevent prolonged hypoglycemia
Follow-up with 24-hour urinary metanephrines at 2-4 weeks (confirm biochemical cure)

PART 3: MOST COMMON VIVA QUESTIONS AND ANSWERS

Q1. What is the "Rule of 10s" for pheochromocytoma?

A: 10% bilateral, 10% extra-adrenal, 10% malignant, 10% in children, 10% familial. Modern data suggests these numbers are higher, especially for hereditary cases (~40%).

Q2. Why must alpha-blockade precede beta-blockade?

A: In a high-catecholamine state, beta-blockade alone blocks vasodilatory β2 receptors while leaving α1 receptors unopposed. This causes severe, unopposed vasoconstriction and can precipitate a life-threatening hypertensive crisis. Alpha-blockade must always come first.

Q3. What is the drug of choice for preoperative alpha-blockade?

A: Phenoxybenzamine - a non-selective, irreversible alpha-1 and alpha-2 blocker. Doxazosin (selective α1 blocker) is increasingly used as it causes less postoperative hypotension due to its competitive (reversible) mechanism.

Q4. How do you assess adequacy of preoperative preparation?

A: Target BP <130/80 mmHg; no BP >160/90 in the last week; orthostatic hypotension (SBP drop >10-20 mmHg on standing); HR 60-80; nasal congestion (sign of alpha-blockade); ECG shows <1 PVC per 5 minutes; no ST changes.

Q5. Which drugs are AVOIDED during anaesthesia for pheochromocytoma and why?

A:

Halothane - sensitizes myocardium to catecholamine-induced arrhythmias

Ketamine - sympathomimetic, increases catecholamine release

Succinylcholine - fasciculations stimulate catecholamine release from tumor

Pancuronium - vagolytic, causes tachycardia

Atracurium - histamine release can cause reflex catecholamine surge

Morphine - histamine release

Droperidol - causes catecholamine release from tumor

Q6. How do you manage a sudden hypertensive crisis during tumor manipulation intraoperatively?

A: First-line: sodium nitroprusside IV infusion (most rapidly titratable). Phentolamine 1-5 mg IV bolus for acute spikes. Nicardipine infusion as alternative. Esmolol for associated tachycardia. Deepen anaesthesia. Temporarily halt surgical manipulation and alert surgeon.

Q7. What happens after ligation of the adrenal vein?

A: Sudden fall in circulating catecholamines causes profound hypotension and vasodilation. Anticipate this - preload with fluids before ligation; have norepinephrine infusion ready; stop vasodilators; prepare vasopressors.

Q8. What is the most feared postoperative complication?

A: Hypotension (in 20-70% of patients) due to the combined effects of persistent alpha-blockade (phenoxybenzamine has a very long half-life), volume depletion, and sudden loss of adrenergic stimulation. Hypoglycemia is also common due to rebound hyperinsulinism.

Q9. What monitoring is mandatory?

A: Intra-arterial line (placed before induction for beat-to-beat BP monitoring), central venous line, ECG, pulse oximetry, ETCO2, urinary catheter, blood glucose monitoring. Swan-Ganz catheter if cardiac compromise present.

Q10. What syndrome is associated with pheochromocytoma?

A: MEN 2A (pheochromocytoma + medullary thyroid carcinoma + hyperparathyroidism), MEN 2B, Von Hippel-Lindau (VHL), Neurofibromatosis type 1 (NF1), and SDH (succinate dehydrogenase) mutations. Always screen for MEN2 before surgery - if MTC is present, thyroid surgery takes precedence.

Q11. What is the preferred vasopressor after tumor removal?

A: Norepinephrine (noradrenaline) infusion is the vasopressor of choice. Phenylephrine (pure alpha) can also be used.

Q12. What anaesthetic agent is preferred for induction?

A: Propofol - reduces sympathetic tone and provides smooth induction. High-dose fentanyl or remifentanil blunts the laryngoscopy pressor response.

PART 4: 10-MARK THEORY ANSWER

Anaesthetic Management of a Patient with Pheochromocytoma

Introduction

Pheochromocytoma is a catecholamine-secreting tumor of the adrenal medulla. It poses one of the greatest anaesthetic challenges due to extreme hemodynamic instability from uncontrolled catecholamine excess. Perioperative mortality has declined from ~50% to <2% with meticulous preoperative preparation, vigilant intraoperative management, and intensive postoperative care.

Preoperative Preparation

Preoperative pharmacological preparation is the cornerstone of safe anaesthesia and must be initiated 2-3 weeks before surgery.

Alpha-adrenergic blockade (mandatory, first step): Phenoxybenzamine, a non-selective irreversible alpha-blocker, is initiated at 10 mg twice daily and titrated to 40 mg/day. Selective alpha-1 blockers such as doxazosin are increasingly preferred. Adequacy is confirmed when: BP is <130/80 mmHg, no paroxysmal hypertension >160/90 in the preceding week, orthostatic hypotension is present (SBP drop >10-20 mmHg on standing), and ECG shows <1 PVC per 5 minutes.

Beta-blockade (only after adequate alpha-blockade): Beta-blockers (propranolol, atenolol) are added only after achieving alpha-blockade to prevent reflex tachycardia. Initiating beta-blockers before alpha-blockers is contraindicated as it causes unopposed alpha-adrenergic stimulation and hypertensive crisis.

Volume expansion: Patients are chronically volume-depleted due to sustained vasoconstriction. High-salt diet, increased oral fluids, and IV fluid preloading (1 L NS) are essential to prevent severe postoperative hypotension.

Additional agents: Calcium channel blockers (nicardipine) may be used as primary agents or adjuncts. Metyrosine (tyrosine hydroxylase inhibitor) is reserved for refractory or high-risk cases.

Preoperative Assessment

Evaluate for end-organ damage: ECG and echocardiogram (catecholamine cardiomyopathy), renal function, fasting glucose, Hb (polycythemia), and 24-hour urine or plasma metanephrines. Screen for associated syndromes (MEN 2, VHL, NF1). Ensure all investigations are optimized before proceeding.

Intraoperative Management

Monitoring: Intra-arterial line is placed before induction for beat-to-beat blood pressure monitoring. Central venous access is mandatory. Continuous ECG, pulse oximetry, ETCO2, urinary catheter, and blood glucose monitoring are essential. Pulmonary artery catheter is reserved for patients with significant cardiac compromise.

Induction: Smooth, stress-free induction is critical. Propofol is the induction agent of choice. High-dose fentanyl or remifentanil blunts the pressor response to laryngoscopy. Vecuronium or rocuronium are preferred muscle relaxants. Drugs to avoid: ketamine (sympathomimetic), halothane (myocardial sensitization), succinylcholine (fasciculations trigger catecholamine surge), pancuronium (vagolytic tachycardia), atracurium (histamine release), and morphine.

Maintenance: Isoflurane or sevoflurane are the preferred volatile agents. Total IV anaesthesia with propofol and remifentanil infusion is an excellent alternative. Adequate depth of anaesthesia is maintained throughout.

Management of intraoperative hypertension: Episodes of severe hypertension during tumor manipulation are managed with: sodium nitroprusside infusion (first choice - rapidly titratable), phentolamine IV boluses (1-5 mg) for acute spikes, nicardipine infusion, and esmolol for associated tachycardia. The surgeon should be asked to temporarily cease manipulation.

After adrenal vein ligation: This critical step causes a sudden catecholamine drop. IV fluid boluses are administered before ligation; vasodilator infusions are stopped; norepinephrine infusion is started to support blood pressure.

Postoperative Management

ICU admission for 24-48 hours is mandatory. The two major complications are:

Hypotension (20-70% of patients) - from loss of catecholamine tone, persistent alpha-blockade (especially with long-acting phenoxybenzamine), and volume depletion. Managed with IV fluids and norepinephrine infusion.
Hypoglycemia - from rebound hyperinsulinism following removal of α2-mediated insulin suppression. Managed with 10% dextrose infusion and hourly blood glucose monitoring.

Blood pressure is monitored continuously. Persistent hypertension may indicate incomplete resection or a second tumor. Biochemical cure is confirmed by 24-hour urine metanephrines at 2-4 weeks postoperatively.

Conclusion

Successful anaesthetic management of pheochromocytoma requires a systematic, team-based approach: adequate preoperative alpha-blockade (with volume expansion), careful avoidance of catecholamine-releasing drugs, vigilant intraoperative hemodynamic control using rapidly titratable agents, and intensive postoperative monitoring for hypotension and hypoglycemia. This multidisciplinary approach - endocrinologist, surgeon, and anaesthesiologist - has transformed the perioperative mortality of this condition.

(~800 words, appropriate for 10-mark theory answer)

Key Sources: Barash, Cullen & Stoelting's Clinical Anesthesia, 9e | Schwartz's Principles of Surgery, 11e | Fischer's Mastery of Surgery, 8e | Goldman-Cecil Medicine | Morgan & Mikhail's Clinical Anesthesiology, 7e

This is a shared conversation. Sign in to Orris to start your own chat.